myeloproliferative neoplasms associated with mutation in jak2v617f and tyrosine kinase inhibitors as therapeutic strategy

Mpns including a heterogeneous group of clonal or oligoclonal hamtopathies characterized by proliferation and accumulation of mature myeloid cells. jak2 tyrosine kinase mutation is the most common molecular lesion identified in 90% of cases. jak2 is involved in epo signaling pathway, and mutations in it lead to epo-independent spontaneous phosphorylation. most tyrosine kinase inhibitors (tki) are small molecules that compete with atp for binding the atp-binding site in tyrosine kinase domains, since atp is a source of phosphate groups used by tks to phosphorylate the target protein.there are many tki agent that are studing for treatment of the mpns with jak2 tyrosine kinase mutation.the most important tki drugs including cep701, cyt387, ly2784544, sb1518, tg101348, xl019, incb18424. most important mechanism of them are reduse the splenomegaly, improvement of constitutional symptoms(improvement of bone marrow fibrosis and anemia). although this drugs are useful but they have some side effect that common of them including gastrointestinal disease (gi), diarrhea, nausea and vomiting, anemia, thrombocytopenia, thrombosis, leukocytosis, thrombocytosis, peripheral neuropathy, transient loss of blood pressure and lightheadedness are the most common side effects.